Also trades as: 0VGI.L (LSE) · $vol 1M
TGTX NASDAQ
TG Therapeutics, Inc.
1W: +3.5%
1M: +0.4%
3M: +5.5%
YTD: +92.8%
1Y: +69.3%
3Y: +736.1%
5Y: +77.0%
$56.44
+1.65 (+3.01%)
Pre-Market: $56.60 (+0.16, +0.28%)
Weekly Expected Move ±4.9%
$49
$52
$54
$57
$59
Credit Risk of going bust: lower than 68% of companies Debt: 8.0% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.46 (down 99.2%), TG Therapeutics, Inc. would be worth roughly what it owes.
Total debt $754.4M against a stock market value of $8.64B.
Distance to default 7.24 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $372.7M (short-term plus half of long-term), stock volatility 45.1%; Altman Z'' 2.57. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.46 (down 99.2%), TG Therapeutics, Inc. would be worth roughly what it owes.
Total debt $754.4M against a stock market value of $8.64B.
Distance to default 7.24 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $372.7M (short-term plus half of long-term), stock volatility 45.1%; Altman Z'' 2.57. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.60
Bullish
2 bullish
1 neutral
0 bearish
Articles (24h)
3
Hourly Sentiment (24h)
0.15
Neutral
5 bullish
4 neutral
3 bearish
Articles (7d)
12
Daily Sentiment (7 Days)
Articles (100)
HCA Healthcare Q3 Earnings Beat Estimates on Higher Admissions
Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Henry Schein to Report Q3 Earnings: Here's What You Should Know
TNGX Stock Falls 16% Despite Positive Pancreatic Cancer Study Data
Incyte & Genmab Collaborate to Develop a New Colorectal Cancer Therapy
RDY Q2 Earnings & Revenues Miss Estimates as Lenalidomide Sales Fall
TG Therapeutics (TGTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
CareDx to Report Q3 Earnings: Transplant Testing Growth in Focus
MRNA Tanks as Positive Phase III Cancer Therapy Data Fails to Impress
Here's How IDEXX Laboratories Is Placed Ahead of Q3 Earnings
Align Technology to Report Q3 Earnings: What's in the Cards?
Labcorp Prepares to Report Q3 Earnings: What's in the Cards?
Humana's CenterWell Expansion Gets a Boost From BlackRock's Capital
Here's How Quest Diagnostics Is Placed Ahead of Q3 Earnings
UNH Tops Q3 Earnings on Lower Medical Costs, Raises '26 Outlook
TGTX Stock Rises 60% in 6 Months: Here's What You Should Know
Thermo Fisher to Report Q3 Earnings: What's in the Cards?
These healthcare stocks stand out with A+ growth grades
Most shorted stocks on Wall Street
Engineers Gate Manager LP Invests $589,000 in TG Therapeutics, Inc. $TGTX
Bank of America Corp DE Acquires Shares of 1,309,788 TG Therapeutics, Inc. $TGTX
Arcutis Biotherapeutics (ARQT) Moves 11.2% Higher: Will This Strength Last?
California State Teachers Retirement System Acquires 9,198,333 Shares of TG Therapeutics, Inc. $TGTX
AXQ Capital LP Takes Position in TG Therapeutics, Inc. $TGTX
Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue?
TG Therapeutics (TGTX) Up 15.1% Since Last Earnings Report: Can It Continue?
Most shorted stocks on Wall Street
Hsbc Holdings PLC Buys Shares of 15,791 TG Therapeutics, Inc. $TGTX
Algert Global LLC Lowers Stock Position in TG Therapeutics, Inc. $TGTX
235,481 Shares in TG Therapeutics, Inc. $TGTX Bought by Deutsche Bank AG
Biggest stock movers Friday: ROST, MSTR, MRVL, HOOD, and more
Bank of America Corp DE Purchases 610,195 Shares of TG Therapeutics, Inc. $TGTX
Assenagon Asset Management S.A. Lowers Stock Position in TG Therapeutics, Inc. $TGTX
SA Asks: What's the outlook for Big Pharma M&A?
Empowered Funds LLC Increases Stake in TG Therapeutics, Inc. $TGTX
TGTX Q2 Earnings Lag, Sales Rise Y/Y, 2026 View Raised, Stock Down
Here's What Key Metrics Tell Us About TG Therapeutics (TGTX) Q2 Earnings
TG Therapeutics (TGTX) Misses Q2 Earnings Estimates
TG Therapeutics GAAP EPS of $0.05 misses by $0.26, revenue of $240.34M beats by $10.55M
TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue Guidance
Here are the major earnings before the open Monday
Earnings Preview: Amgen (AMGN) Q2 Earnings Expected to Decline
TG Therapeutics (TGTX) to Report Q2 Results: Wall Street Expects Earnings Growth
Bleakley Financial Group LLC Makes New Investment in TG Therapeutics, Inc. $TGTX
2 Fast-Growing Pharmaceutical Stocks to Buy Now
TG Therapeutics Begins Phase II Study With Briumvi in Schizophrenia
Will Briumvi's Strength Continue to Aid TGTX's Top Line in Q2?
Immunovant (IMVT) Up 3.6% Since Last Earnings Report: Can It Continue?
TG Therapeutics Stock Rises Thursday: What's Driving The Gains?
TG Therapeutics (TGTX) Soars 7.5%: Is Further Upside Left in the Stock?
TG Therapeutics Stock Is Surging Today: What's Driving The Action?
Caseys General Stores Upbeat Q4 Earnings, Joins Applied Optoelectronics, Clover Health Investments And Other Big Stocks Moving Higher On Wednesday
TGTX Rises on Positive Phase I Data for Subcutaneous Briumvi in MG
Why Is TG Therapeutics Stock Gaining Tuesday?
TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial
Why Is TG Therapeutics (TGTX) Down 5.7% Since Last Earnings Report?
Mid-cap companies with strong growth at modest valuations
TGTX Stock Up on Positive Phase I Data for Subcutaneous Briumvi
TG Therapeutics Stock Surges After Drug Trial Update
Navitas Semiconductor, Abivax, MiniMed And Other Big Stocks Moving Higher On Wednesday
TG Therapeutics to Participate in the Goldman Sachs 47th Annual Healthcare Conference
TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in Immunology
TGTX's Single-Dose Briumvi Hits Bioequivalence Goal in MS Study
TG Therapeutics Announces Data Presentations for BRIUMVI® at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting
TGTX Stock Rises 29% in 3 Months: Here's What You Should Know
TGTX Q1 Earnings Miss, Sales Rise Y/Y, Stock Up on Raised 2026 View
Earnings Scheduled For May 6, 2026
TG Therapeutics (TGTX) Q1 2026 Earnings Transcript
TGTX Q1 2025 Earnings Call Transcript
TG Therapeutics outlines $925M 2026 global revenue guidance while targeting ~$220M Q2 U.S. BRIUMVI net revenue
TG Therapeutics (TGTX) Q1 Earnings Lag Estimates
TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance
TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance
Here are the major earnings before the open Wednesday
TG Therapeutics Q1 2026 Earnings Preview
TG Therapeutics to Host Conference Call on First Quarter 2026 Financial Results and Business Update
Fortrea Holdings Inc. (FTRE) Reports Next Week: Wall Street Expects Earnings Growth
TG Therapeutics (TGTX) to Report Q1 Results: Wall Street Expects Earnings Growth
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting
TGTX Completes Enrollment in Phase III Study on Subcutaneous Briumvi
SG Americas Securities LLC Acquires 16,982 Shares of TG Therapeutics, Inc. $TGTX
Ocugen (OCGN) Up 2.9% Since Last Earnings Report: Can It Continue?
TG Therapeutics, Inc. $TGTX Shares Bought by JPMorgan Chase & Co.
TG Therapeutics, Inc. $TGTX Shares Purchased by Assenagon Asset Management S.A.
1,922,410 Shares in TG Therapeutics, Inc. $TGTX Acquired by Congress Asset Management Co.
TG Therapeutics secures $750M credit facility with Blue Owl, boosts buyback to $300M
TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 Million
This Biotech With a Breakout MS Drug Draws $8 Million Investment Amid 30% Stock Drop
Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis
TGTX Q4 Earnings Lag Estimates, Briumvi Sales Drive Top Line
TG Therapeutics: 'Strong Buy' On BRIUMVI's Massive Growth And Possible Expansion
TGTX Q4 Earnings Lag Estimates, Briumvi Sales Drive Top Line
TG Therapeutics GAAP EPS of $0.14 misses by $0.21, revenue of $192.6M misses by $0.74M
TG Therapeutics, Inc. (TGTX) Q4 2025 Earnings Call Transcript
TG Therapeutics (TGTX) Misses Q4 Earnings Estimates
TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance
TG Therapeutics Q4 2025 Earnings Preview
TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q4 Release
TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results and Business Update
TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Average Rating of “Moderate Buy” from Brokerages